

THERAPEUTIC TREATMENT FOR THE METABOLIC SYNDROME
AND TYPE 2 DIABETES

5

ABSTRACT OF THE DISCLOSURE

The present invention is directed to a method for treating the metabolic syndrome or Type 2 diabetes, comprising the step of administering to a subject in need of such treatment a pharmaceutical composition comprising (1) at least one compound that stimulates an increase in central dopaminergic neuronal activity level in the subject, and (2) at least one compound that stimulates a decrease in central noradrenergic neuronal activity level in the subject. The present invention is also directed to a method for treating the metabolic syndrome or Type 2 diabetes, comprising the step of administering to a subject in need of such treatment at least one compound that simultaneously stimulates (1) an increase in central dopaminergic neuronal activity level, and (2) a decrease in central noradrenergic neuronal activity level. The present invention is also directed to pharmaceutical compositions that include the above compounds and a pharmaceutically acceptable carrier.

20

\15546\5\414053.1

25